ParcelBio, a biotech startup, has unveiled a programmable mRNA platform supported by $13 million in new financing. The platform targets autoimmune diseases, oncology, and encoded protein therapeutics, aiming to expand the therapeutic reach of mRNA technology beyond vaccines.
The company plans to present preclinical data demonstrating the platform's efficacy at the upcoming ASGCT meeting. Details on specific efficacy rates or patient populations were not disclosed in the announcement, though the data will likely address the platform's ability to program mRNA for diverse therapeutic applications.